Trials / Completed
CompletedNCT01139307
Biomarkers in Samples From Patients With Down Syndrome and Acute Megakaryoblastic Leukemia
Development of Novel Therapeutics for AMKL
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (estimated)
- Sponsor
- Children's Oncology Group · Network
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Studying samples of blood or tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in samples from patients with Down syndrome and acute megakaryoblastic leukemia.
Detailed description
OBJECTIVES: * Determine whether megakaryocyte differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor can lead to proliferation arrest, polyploidization, and terminal differentiation of blasts in specimens from patients with Down syndrome and acute megakaryoblastic leukemia. OUTLINE: Cryopreserved specimens are cultured and treated in vivo (in mice) and in vitro with megakaryocytic differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | cell culture procedure | |
| OTHER | laboratory biomarker analysis |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2012-08-01
- First posted
- 2010-06-08
- Last updated
- 2016-02-23
Source: ClinicalTrials.gov record NCT01139307. Inclusion in this directory is not an endorsement.